TYRA
Tyra Biosciences, Inc.
There isn't enough reported data to score TYRA yet.
TYRA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
TYRA's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
TYRA PE Valuation
TYRA has no meaningful PE right now: it lost money over the past year.
TYRA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect TYRA's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
TYRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.64 | -$0.77 |
| Q2 2026 | -$2.40 | -$0.62 |
| Q1 2026 | -$2.18 | -$0.55 |
| Q4 2025 | -$2.01 | -$0.50 |
| Q3 2025 | -$1.87 | -$0.25 |
| Q2 2025 | -$1.78 | -$0.08 |
| Q1 2025 | -$1.63 | +$0.06 |
| Q4 2024 | -$1.51 | +$0.11 |
TYRA lost $2.64 per share over the past year, a bigger loss than the year before.
TYRA Quarterly Revenue
TYRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$32.3M | -$9.9M |
| Q2 2026 | -$31.1M | -$7.4M |
| Q1 2026 | -$32.7M | -$7.2M |
| Q4 2025 | -$23.7M | -$4.1M |
| Q3 2025 | -$22.4M | -$4.5M |
| Q2 2025 | -$23.7M | -$13M |
| Q1 2025 | -$25.5M | -$3.3M |
| Q4 2024 | -$19.6M | -$5.5M |
TYRA has burned cash in almost every quarter: −$120M over the past year, against −$91M the year before.
TYRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +3.1M shares |
| 1 year | +16% | +9.4M shares |
| 3 years | +61% | +26.2M shares |
| 5 years | +88% | +32.3M shares |
TYRA has 69M diluted shares, up 16% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TYRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -69.2x | Net Cash |
| Q4 2021 | -20.4x | Net Cash |
| Q3 2021 | -14.9x | Net Cash |
TYRA has more cash than debt.
TYRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.8 | Neutral |
| Stochastic | 17.3 | Oversold |
TYRA's weekly RSI is 40 (neutral) and its Stochastic is 17 (oversold).
TYRA PE vs Healthcare Sector
TYRA has no meaningful PE right now: it lost money over the past year.
TYRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.4 | 3% below |
| 20 week MA | $25.0 | 21% below |
| 50 week MA | $28.9 | 32% below |
| 100 week MA | $20.6 | 4% below |
| 200 week MA | $18.3 | 7.9% above |
TYRA has fallen below most of its moving averages, though it's still 7.9% above its 200-week average.
TYRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $19.9 | $14.8 | -26% |
| 2022 | $14.8 | $8.81 | -41% |
| 2023 | $8.81 | $13.9 | +57% |
| 2024 | $13.9 | $14.1 | +1.6% |
| 2025 | $14.1 | $26.0 | +85% |
| 2026 YTD | $26.0 | $19.8 | -24% |
TYRA has finished higher in three of the last five years, two of them by more than 50%. It's down 24% so far in 2026.